MétaCan
Menu
Back to cohort
Record W4406946410 · doi:10.1093/ofid/ofae631.810

P-612. Effectiveness of Live Attenuated and Inactivated Influenza Vaccines in Children: Data from the 2023/24 Influenza Season

2025· article· en· W4406946410 on OpenAlexaboutno aff
Allyn Bandell, Chris Barker, Oliver Dibben

Bibliographic record

VenueOpen Forum Infectious Diseases · 2025
Typearticle
Languageen
FieldMedicine
TopicInfluenza Virus Research Studies
Canadian institutionsnot available
Fundersnot available
KeywordsMedicineInfluenza seasonVirologyLive attenuated influenza vaccineInfluenza vaccineVaccination

Abstract

fetched live from OpenAlex

Abstract Background Annual vaccination with a live attenuated influenza vaccine (LAIV) or inactivated influenza vaccine (IIV) is the most effective way to protect children from the burden of influenza infection, and to reduce the potential for transmission to family members and the community. Here we report vaccine effectiveness (VE) from data reported globally for LAIV and IIV in children from the 2023/24 influenza season. Methods Quadrivalent LAIV and IIV effectiveness studies conducted in children in the 2023/24 influenza season were identified from published literature and public health websites. Studies from Canada, Finland, the UK, the US, and a European-wide study in 10 countries, reporting VE data for any influenza infection (all strains), by strain type (all influenza A, A/H3N2, and A/H1N1pdm09), and by vaccination setting (primary/outpatient care and hospital) were included. Results In five studies reporting on influenza infections (all strains) in children with ages ranging from 6 months to 19 years across studies, VE estimates for LAIV ranged from 36% (95% CI: 21–48) in Finland to 65% (95% CI: 41–79) in the UK, and for IIV ranged from 59% (95% CI: 48–67) to 67% (95% CI: 48–80) in the US. When analyzed by vaccination setting, VE against any influenza, influenza A, A/H3N2, and A/H1N1pdm09 in all the included countries ranged from 36–65% for LAIV and 46–85% for IIV in children in primary/outpatient care (Figure 1). For hospitalized children, VE against any influenza, influenza A, A/H3N2, and A/H1N1pdm09 in all the included countries ranged from 25–80% for LAIV and 46–61% for IIV (Figure 2). Where available, VE data against influenza A, A/H3N2, and A/H1N1pdm09 were comparable for both LAIV and IIV in children in primary/outpatient care and hospitalized children. Conclusion VE data for the 2023/24 season from global reports show LAIV and IIV demonstrated comparable moderate protection for children against influenza infection. These early VE data were similar across the included healthcare settings of outpatient/primary care and hospitals. Disclosures Allyn R. Bandell, PharmD, AstraZeneca: Stocks/Bonds (Public Company) Chris Barker, PhD, AstraZeneca: Stocks/Bonds (Public Company) Oliver Dibben, PhD, AstraZeneca: Stocks/Bonds (Public Company)

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.010
metaresearch head score (Gemma)0.023
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.026
Threshold uncertainty score0.052

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0100.023
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.006
Bibliometrics0.0050.007
Science and technology studies0.0000.000
Scholarly communication0.0010.001
Open science0.0010.001
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0050.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.047
GPT teacher head0.382
Teacher spread0.335 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueOpen Forum Infectious DiseasesSame topicInfluenza Virus Research StudiesFrench-language works237,207